{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:03:42Z","timestamp":1790345022899,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TRR241"],"award-info":[{"award-number":["TRR241"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TRR417"],"award-info":[{"award-number":["TRR417"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFFB1181"],"award-info":[{"award-number":["SFFB1181"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009379","name":"Interdisziplin\u00e4res Zentrum f\u00fcr Klinische Forschung, Universit\u00e4tsklinikum W\u00fcrzburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009379","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ero.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EULAR Rheumatology Open"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ero.2026.100224","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T06:37:22Z","timestamp":1786948642000},"page":"100224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["CAR-T cells and CAR-Treg cells for treatment of inflammatory bowel diseases"],"prefix":"10.1016","volume":"2","author":[{"given":"Markus F","family":"Neurath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ero.2026.100224_bib0001","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.2174\/138945011796818207","article-title":"Ulcerative colitis: a cinderella story","volume":"12","author":"Danese","year":"2011","journal-title":"Curr Drug Targets."},{"key":"10.1016\/j.ero.2026.100224_bib0002","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1136\/gutjnl-2011-300904","article-title":"New therapies for inflammatory bowel disease: from the bench to the bedside","volume":"61","author":"Danese","year":"2012","journal-title":"Gut."},{"key":"10.1016\/j.ero.2026.100224_bib0003","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for crohn's disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ero.2026.100224_bib0004","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of response to Anti-TNFs: definition, epidemiology, and management","volume":"7","author":"Roda","year":"2016","journal-title":"Clin Transl Gastroenterol."},{"key":"10.1016\/j.ero.2026.100224_bib0005","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10620-024-08792-0","article-title":"Small molecules, big results: how JAK inhibitors have transformed the treatment of patients with IBD","volume":"70","author":"Fansiwala","year":"2025","journal-title":"Dig Dis Sci."},{"key":"10.1016\/j.ero.2026.100224_bib0006","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.dld.2021.11.014","article-title":"Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis","volume":"54","author":"Attauabi","year":"2022","journal-title":"Dig Liver Dis."},{"key":"10.1016\/j.ero.2026.100224_bib0007","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"10.1016\/j.ero.2026.100224_bib0008","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1053\/j.gastro.2022.01.047","article-title":"Guselkumab for the treatment of Crohn's disease: induction results from the phase 2 GALAXI-1 study","volume":"162","author":"Sandborn","year":"2022","journal-title":"Gastroenterology."},{"key":"10.1016\/j.ero.2026.100224_bib0009","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003417","article-title":"Circulating cytokines and cytokine receptors in infliximab treatment failure due to TNF-alpha independent Crohn disease","volume":"95","author":"Steenholdt","year":"2016","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.ero.2026.100224_bib0010","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41591-022-01680-y","article-title":"Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity","volume":"28","author":"Uzzan","year":"2022","journal-title":"Nat Med."},{"key":"10.1016\/j.ero.2026.100224_bib0011","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/gutjnl-2024-332919","article-title":"Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet?","volume":"74","author":"Neurath","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.ero.2026.100224_bib0012","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1182\/bloodadvances.2023010364","article-title":"Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R\/R DLBCL","volume":"7","author":"Blumenberg","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.ero.2026.100224_bib0013","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ero.2026.100224_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100749","article-title":"Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission","volume":"6","author":"Wang","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.ero.2026.100224_bib0015","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1182\/blood.2025028375","article-title":"Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma","volume":"1469","author":"M\u00fcller","year":"2025","journal-title":"Blood."},{"key":"10.1016\/j.ero.2026.100224_bib0016","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ero.2026.100224_bib0017","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3892\/mmr.2024.13171","article-title":"CAR\u2011T cell therapy: a breakthrough in traditional cancer treatment strategies (Review)","volume":"29","author":"Sun","year":"2024","journal-title":"Mol Med Rep."},{"key":"10.1016\/j.ero.2026.100224_bib0018","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s10238-025-01820-x","article-title":"Emerging CAR immunotherapies: broadening therapeutic horizons beyond cancer","volume":"25","author":"Sueangoen","year":"2025","journal-title":"Clin Exp Med."},{"key":"10.1016\/j.ero.2026.100224_bib0019","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJMc2509522","article-title":"In vivo CD19 CAR T-Cell therapy for refractory systemic lupus erythematosus","volume":"393","author":"Wang","year":"2025","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ero.2026.100224_bib0020","article-title":"CAR-T therapy: pioneering a new era in the treatment of autoimmune diseases","volume":"16","author":"Wu","year":"2025","journal-title":"Front Immunol."},{"key":"10.1016\/j.ero.2026.100224_bib0021","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med."},{"key":"10.1016\/j.ero.2026.100224_bib0022","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/s41590-019-0415-0","article-title":"Targeting immune cell circuits and trafficking in inflammatory bowel disease","volume":"20","author":"Neurath","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ero.2026.100224_bib0023","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/mi.2013.73","article-title":"New targets for mucosal healing and therapy in inflammatory bowel diseases","volume":"7","author":"Neurath","year":"2014","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.ero.2026.100224_bib0024","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nrgastro.2017.136","article-title":"Environmental triggers in IBD: a review of progress and evidence","volume":"15","author":"Ananthakrishnan","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"10.1016\/j.ero.2026.100224_bib0025","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMra1102942","article-title":"Ulcerative colitis","volume":"365","author":"Danese","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ero.2026.100224_bib0026","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjae131","article-title":"Integrin alphaVbeta6: autoantigen and driver of epithelial remodeling in colon and bile ducts in primary sclerosing cholangitis and inflammatory bowel disease","volume":"19","author":"Roth","year":"2025","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.ero.2026.100224_bib0027","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/jpn3.70444","article-title":"Anti-integrin alphavbeta6 Immunoglobulin G antibodies are detected in pediatric colonic Crohn's disease","volume":"83","author":"Ziberna","year":"2026","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"10.1016\/j.ero.2026.100224_bib0028","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.192953","article-title":"Characteristics of anti-integrin alphavbeta6 autoantibodies in patients with ulcerative colitis","volume":"11","author":"Takimoto","year":"2026","journal-title":"JCI insight."},{"key":"10.1016\/j.ero.2026.100224_bib0029","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/ecco-jcc\/jjad087","article-title":"A comparative evaluation of the measurement properties of three histological indices of mucosal healing in ulcerative colitis: Geboes Score, Robarts Histopathology Index, and Nancy Index","volume":"17","author":"Peyrin-Biroulet","year":"2023","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.ero.2026.100224_bib0030","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/gutjnl-2015-310187","article-title":"Development and validation of the Nancy histological index for UC","volume":"66","author":"Marchal-Bressenot","year":"2017","journal-title":"Gut."},{"key":"10.1016\/j.ero.2026.100224_bib0031","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1093\/ibd\/izab340","article-title":"Histologic evaluation using the robarts histopathology index in patients with ulcerative colitis in deep remission and the association of histologic remission with risk of relapse","volume":"28","author":"Park","year":"2022","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.ero.2026.100224_bib0032","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/ecco-jcc\/jjab055","article-title":"Validation of the \u2018Inflammatory Bowel Disease-Distribution, Chronicity, Activity [IBD-DCA] Score\u2019 for ulcerative colitis and Crohn\u2019s disease","volume":"15","author":"Lang-Schwarz","year":"2021","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.ero.2026.100224_bib0033","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1136\/gut.2010.225482","article-title":"Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis","volume":"60","author":"Leiper","year":"2011","journal-title":"Gut."},{"key":"10.1016\/j.ero.2026.100224_bib0034","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/ibd.20215","article-title":"Exacerbation of ulcerative colitis after rituximab salvage therapy","volume":"13","author":"Goetz","year":"2007","journal-title":"Inflammatory bowel diseases."},{"key":"10.1016\/j.ero.2026.100224_bib0035","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/nyas.13577","article-title":"Efficient long-term depletion of CD20(+) B cells by rituximab does not affect gut-resident plasma cells","volume":"1415","author":"Uzzan","year":"2018","journal-title":"Ann N Y Acad Sci."},{"key":"10.1016\/j.ero.2026.100224_bib0036","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1056\/NEJMc2508023","article-title":"CD19 CAR T-Cell therapy in multidrug-resistant ulcerative colitis","volume":"393","author":"M\u00fcller","year":"2025","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ero.2026.100224_bib0037","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1038\/s41591-025-03937-8","article-title":"Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial","volume":"31","author":"Feng","year":"2025","journal-title":"Nat Med."},{"key":"10.1016\/j.ero.2026.100224_bib0038","doi-asserted-by":"crossref","DOI":"10.1097\/BS9.0000000000000247","article-title":"CD7 CAR-T therapy: current developments, improvements, and dilemmas","volume":"7","author":"Wang","year":"2025","journal-title":"Blood Sci."},{"key":"10.1016\/j.ero.2026.100224_bib0039","doi-asserted-by":"crossref","first-page":"403","DOI":"10.12968\/jowc.2010.19.9.78235","article-title":"TGF-ss in wound healing: a review","volume":"19","author":"Douglas","year":"2010","journal-title":"J Wound Care."},{"key":"10.1016\/j.ero.2026.100224_bib0040","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3748\/wjg.v17.i17.2161","article-title":"Wound healing of intestinal epithelial cells","volume":"17","author":"Iizuka","year":"2011","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ero.2026.100224_bib0041","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1084\/jem.20082683","article-title":"STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing","volume":"206","author":"Pickert","year":"2009","journal-title":"J Exp Med."},{"key":"10.1016\/j.ero.2026.100224_bib0042","article-title":"IL23R-Specific CAR Tregs for the treatment of Crohn's disease","volume":"19","author":"Cui","year":"2025","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.ero.2026.100224_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2026.114988","article-title":"CAR Treg therapies for neurodegenerative diseases","volume":"29","author":"Stein","year":"2026","journal-title":"iScience."},{"key":"10.1016\/j.ero.2026.100224_bib0044","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1509956","article-title":"From promise to practice: CAR T and Treg cell therapies in autoimmunity and other immune-mediated diseases","volume":"15","author":"Bulliard","year":"2024","journal-title":"Front Immunol."},{"key":"10.1016\/j.ero.2026.100224_bib0045","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1126\/science.1242674","article-title":"Immunology. Feed your tregs more fiber","volume":"341","author":"Bollrath","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ero.2026.100224_bib0046","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1053\/j.gastro.2005.03.043","article-title":"Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease","volume":"128","author":"Maul","year":"2005","journal-title":"Gastroenterology."},{"key":"10.1016\/j.ero.2026.100224_bib0047","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nri3661","article-title":"Cytokines in inflammatory bowel disease","volume":"14","author":"Neurath","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ero.2026.100224_bib0048","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjae159","article-title":"IL-23R-Specific chimeric antigen receptor tregs in Crohn's disease: dawn of a cellular immunotherapeutic era?","volume":"19","author":"Atreya","year":"2025","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.ero.2026.100224_bib0049","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1038\/s41591-026-04430-6","article-title":"Resetting autoimmune disease with CAR cell therapies","volume":"32","author":"Schett","year":"2026","journal-title":"Nat Med."},{"key":"10.1016\/j.ero.2026.100224_bib0050","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/d41573-021-00194-5","article-title":"The market for ulcerative colitis","volume":"21","author":"Al-Horani","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ero.2026.100224_bib0051","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1007\/s10620-021-07025-y","article-title":"Patient perspectives and expectations in inflammatory bowel disease: a systematic review","volume":"67","author":"Al Khoury","year":"2022","journal-title":"Dig Dis Sci."},{"key":"10.1016\/j.ero.2026.100224_bib0052","first-page":"806","article-title":"Efficacy and safety of re-induction treatment with the selective IL-23 inhibitor risankizumab in patients with moderate to severe Crohn\u00b4s disease","volume":"4","author":"Feagan","year":"2016","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.ero.2026.100224_bib0053","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2208450","article-title":"Vedolizumab for the treatment of chronic pouchitis","volume":"388","author":"Travis","year":"2023","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ero.2026.100224_bib0054","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41573-025-01291-5","article-title":"In vivo chimeric antigen receptor (CAR)-T cell therapy","volume":"25","author":"Bot","year":"2025","journal-title":"Nat Rev Drug Discov."},{"key":"10.1016\/j.ero.2026.100224_bib0055","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science."},{"key":"10.1016\/j.ero.2026.100224_bib0056","article-title":"Engineering the next generation of CAR T- cells: precision modifications, logic gates and universal strategies to overcome exhaustion and tumor resistance","volume":"15","author":"Garcia-Robledo","year":"2025","journal-title":"Front Oncol."},{"key":"10.1016\/j.ero.2026.100224_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/s41575-026-01226-4","article-title":"Engineering immune cell therapies for inflammatory bowel disease: from stem cells to CAR T cells","author":"Neurath","year":"2026","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["EULAR Rheumatology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708126001230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708126001230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:29:22Z","timestamp":1790342962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050708126001230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S3050708126001230"],"URL":"https:\/\/doi.org\/10.1016\/j.ero.2026.100224","relation":{},"ISSN":["3050-7081"],"issn-type":[{"value":"3050-7081","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR-T cells and CAR-Treg cells for treatment of inflammatory bowel diseases","name":"articletitle","label":"Article Title"},{"value":"EULAR Rheumatology Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ero.2026.100224","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}],"article-number":"100224"}}